BACKGROUND


OBJECTIVE

To compare the effectiveness of treatment with everolimus, temsirolimus and sorafenib following initial targeted therapy with a TKI.

RESULTS

Overall and Progression-free Survival with Everolimus, Temsirolimus or Sorafenib as Second Targeted Therapies for Metastatic Renal Cell Carcinoma: A Retrospective US Chart Review

Hongyi Yang, Michael K.K. Wong, James E. Signorelli, Xiaogang Wang, Zhengui Liu, Nathan S. Liu, Zhengguo Qian, Daniel J. George

Analytic Group, Inc., Boston, MA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Novartis Pharmaceuticals Corporation, Rutherford, NJ, USA; Duke University Medical Center, Durham, NC, USA

Overall and Progression-free Survival with Everolimus, Temsirolimus or Sorafenib as Second Targeted Therapies for Metastatic Renal Cell Carcinoma: A Retrospective US Chart Review

Hongyi Yang, Michael K.K. Wong, James E. Signorelli, Xiaogang Wang, Zhengui Liu, Nathan S. Liu, Zhengguo Qian, Daniel J. George

Analytic Group, Inc., Boston, MA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Novartis Pharmaceuticals Corporation, Rutherford, NJ, USA; Duke University Medical Center, Durham, NC, USA

overallOS

Overall and Progression-free Survival with Everolimus, Temsirolimus or Sorafenib as Second Targeted Therapies for Metastatic Renal Cell Carcinoma: A Retrospective US Chart Review

Hongyi Yang, Michael K.K. Wong, James E. Signorelli, Xiaogang Wang, Zhengui Liu, Nathan S. Liu, Zhengguo Qian, Daniel J. George

Analytic Group, Inc., Boston, MA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; Novartis Pharmaceuticals Corporation, Rutherford, NJ, USA; Duke University Medical Center, Durham, NC, USA

REFERENCE

RAW TEXT END